Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.
Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.
The report details the trend, potential and market size of Glioblastoma Multiforme Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Glioblastoma Multiforme Therapeuticsmarket, defines the market attractiveness level of Glioblastoma Multiforme Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Glioblastoma Multiforme Therapeutics industry, describes the types of Glioblastoma Multiforme Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Glioblastoma Multiforme Therapeutics market and the development prospects and opportunities of Glioblastoma Multiforme Therapeutics industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Glioblastoma Multiforme Therapeutics market in Chapter 13.
By Player:
Arbor Pharmaceuticals
Merck
F Hoffmann-La Roche
Eisai
Bristol-Myers Squibb
By Type:
Temozolomide
Bevacozumab
Carmustine
By End-User:
Hospitals
Clinics
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Glioblastoma Multiforme Therapeutics Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Glioblastoma Multiforme Therapeutics Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Glioblastoma Multiforme Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Glioblastoma Multiforme Therapeutics Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Glioblastoma Multiforme Therapeutics Market Analysis and Outlook to 2022
-
7.1 Global Glioblastoma Multiforme Therapeutics Consumption (2017-2022)
-
7.2 United States Glioblastoma Multiforme Therapeutics Consumption (2017-2022)
-
7.3 Europe Glioblastoma Multiforme Therapeutics Consumption (2017-2022)
-
7.4 China Glioblastoma Multiforme Therapeutics Consumption (2017-2022)
-
7.5 Japan Glioblastoma Multiforme Therapeutics Consumption (2017-2022)
-
7.6 India Glioblastoma Multiforme Therapeutics Consumption (2017-2022)
-
7.7 South Korea Glioblastoma Multiforme Therapeutics Consumption (2017-2022)
8 Region and Country-wise Glioblastoma Multiforme Therapeutics Market Analysis and Outlook to 2028
-
8.1 Global Glioblastoma Multiforme Therapeutics Consumption Forecast (2022-2028)
-
8.2 United States Glioblastoma Multiforme Therapeutics Consumption Forecast (2022-2028)
-
8.3 Europe Glioblastoma Multiforme Therapeutics Consumption Forecast (2022-2028)
-
8.4 China Glioblastoma Multiforme Therapeutics Consumption Forecast (2022-2028)
-
8.5 Japan Glioblastoma Multiforme Therapeutics Consumption Forecast (2022-2028)
-
8.6 India Glioblastoma Multiforme Therapeutics Consumption Forecast (2022-2028)
-
8.7 South Korea Glioblastoma Multiforme Therapeutics Consumption Forecast (2022-2028)
9 Global Glioblastoma Multiforme Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Glioblastoma Multiforme Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Temozolomide Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Bevacozumab Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Carmustine Consumption and Growth Rate (2017-2022)
-
9.2 Global Glioblastoma Multiforme Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global Glioblastoma Multiforme Therapeutics Market Outlook by Types and Applications to 2028
-
10.1 Global Glioblastoma Multiforme Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Temozolomide Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Bevacozumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Carmustine Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Glioblastoma Multiforme Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Glioblastoma Multiforme Therapeutics Import and Export Analysis (Top 5 Countries)
-
11.1 Global Glioblastoma Multiforme Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Glioblastoma Multiforme Therapeutics Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Glioblastoma Multiforme Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Glioblastoma Multiforme Therapeutics Market Competitive Analysis
-
14.1 Arbor Pharmaceuticals
-
14.1.1 Arbor Pharmaceuticals Company Details
-
14.1.2 Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Product and Service
-
14.2 Merck
-
14.2.1 Merck Company Details
-
14.2.2 Merck Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Merck Glioblastoma Multiforme Therapeutics Product and Service
-
14.3 F Hoffmann-La Roche
-
14.3.1 F Hoffmann-La Roche Company Details
-
14.3.2 F Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 F Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Product and Service
-
14.4 Eisai
-
14.4.1 Eisai Company Details
-
14.4.2 Eisai Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Eisai Glioblastoma Multiforme Therapeutics Product and Service
-
14.5 Bristol-Myers Squibb
-
14.5.1 Bristol-Myers Squibb Company Details
-
14.5.2 Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Glioblastoma Multiforme Therapeutics
-
Figure Glioblastoma Multiforme Therapeutics Picture
-
Table Global Glioblastoma Multiforme Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Glioblastoma Multiforme Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Glioblastoma Multiforme Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Glioblastoma Multiforme Therapeutics Consumption by Country (2017-2022)
-
Figure United States Glioblastoma Multiforme Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Glioblastoma Multiforme Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure China Glioblastoma Multiforme Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Glioblastoma Multiforme Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Glioblastoma Multiforme Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Glioblastoma Multiforme Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Global Glioblastoma Multiforme Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Glioblastoma Multiforme Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Glioblastoma Multiforme Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Glioblastoma Multiforme Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Glioblastoma Multiforme Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Glioblastoma Multiforme Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Glioblastoma Multiforme Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Temozolomide Consumption and Growth Rate (2017-2022)
-
Figure Global Bevacozumab Consumption and Growth Rate (2017-2022)
-
Figure Global Carmustine Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Temozolomide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Bevacozumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Carmustine Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Glioblastoma Multiforme Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Glioblastoma Multiforme Therapeutics Export by Region (Top 5 Countries) (2017-2028)
-
Table Arbor Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Glioblastoma Multiforme Therapeutics Product and Service
-
Table F Hoffmann-La Roche (Foundation Year, Company Profile and etc.)
-
Table F Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Product and Service
-
Table Eisai (Foundation Year, Company Profile and etc.)
-
Table Eisai Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eisai Glioblastoma Multiforme Therapeutics Product and Service
-
Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)
-
Table Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Product and Service
-
